CA Patent

CA1242699A — Cefbuperazone and derivatives thereof

Assigned to Bristol Myers Co · Expires 1988-10-04 · 38y expired

What this patent protects

Abstract of the Disclosure Cefbuperazone hemiacetonate is a stable, non-hygro-scopic form of cefbuperazone. Dry mixes comprising cefbuperazone free acid dihydrate, anhydrous cefbuperazone free acid or cefbuper-azone hemiacetonate and lysine, arginine, lysine acetate, arginine ac…

USPTO Abstract

Abstract of the Disclosure Cefbuperazone hemiacetonate is a stable, non-hygro-scopic form of cefbuperazone. Dry mixes comprising cefbuperazone free acid dihydrate, anhydrous cefbuperazone free acid or cefbuper-azone hemiacetonate and lysine, arginine, lysine acetate, arginine acetate, or a mixture thereof, are stable in the dry state and, when reconstituted, produce low pain upon injection.

Drugs covered by this patent

Patent Metadata

Patent number
CA1242699A
Jurisdiction
CA
Classification
—
Expires
1988-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.